e-learning
resources
Vienna 2012
Monday, 03.09.2012
Scores, biomarkers and risk factors in respiratory infections
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Procalcitonin and proadrenomedullin in COPD patients: Stable state versus exacerbation difference in mortality rate?
M.C. Telgen, M.G.J. Brusse-Keizer, P.D.L.P.M. van der Valk, J. van der Palen, H.A.M. Kerstjens, M.G.R. Hendrix (Enschede, Netherlands)
Source:
Annual Congress 2012 - Scores, biomarkers and risk factors in respiratory infections
Session:
Scores, biomarkers and risk factors in respiratory infections
Session type:
Thematic Poster Session
Number:
2502
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M.C. Telgen, M.G.J. Brusse-Keizer, P.D.L.P.M. van der Valk, J. van der Palen, H.A.M. Kerstjens, M.G.R. Hendrix (Enschede, Netherlands). Procalcitonin and proadrenomedullin in COPD patients: Stable state versus exacerbation difference in mortality rate?. Eur Respir J 2012; 40: Suppl. 56, 2502
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Stable state fibrinogen is additive to MR-proADM as a predictor of mortality in COPD patients
Source: International Congress 2015 – Monitoring and phenotyping COPD
Year: 2015
Circulating copeptin is associated with mortality irrespectively of exacerbation rate in stable COPD
Source: International Congress 2014 – COPD - from biomarkers to novel therapeutic opportunities
Year: 2014
Does serum uric acid levels predict in-hospital mortality in severe COPD exacerbations?
Source: International Congress 2015 – COPD: interesting notes
Year: 2015
Role of comorbidities in stable COPD patients mortality
Source: International Congress 2016 – Monitoring comorbidities
Year: 2016
LATE-BREAKING ABSTRACT: Elevated cardiovascular risk as measured by QRISK2 score in patients hospitalized for acute COPD exacerbation
versus
stable COPD outpatients
Source: International Congress 2014 – Comorbidities
Year: 2014
Does higher DECAF score increase length of hospital stay in acute exacerbation of COPD?
Source: International Congress 2016 – Exploring mechanisms in health and disease
Year: 2016
CRP as predictor as predictor for late treatment failure in hospitalised patients with AECOPD
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
Aspergillus in COPD patients; is it a predictor for mortality?
Source: International Congress 2016 – In-patient and out-patient COPD management
Year: 2016
Determinants of exacerbation rate in patients with stable COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 661s
Year: 2004
Under reporting acute exacerbation in patient with COPD: incidence and predictors?
Source: Eur Respir J 2006; 28: Suppl. 50, 175s
Year: 2006
COPD: Plasma surfactant protein-D (SPD) concentration as a predictor of acute exacerbations (AE) probability
Source: International Congress 2016 – Features and impact of comorbidities in COPD
Year: 2016
In hospitalized COPD exacerbation (COPDE) patients a 30-day readmission is associated with a progressive increased risk of mortality
Source: International Congress 2015 – COPD: interesting notes
Year: 2015
MR-proANP predicts 2-year survival in patients admitted for acute exacerbation of COPD
Source: Annual Congress 2009 - Exacerbations of COPD: new findings
Year: 2009
COPD: Acute exacerbation (AE) rate and saturation in the patients with different plasma surfactant protein D (SP-D) level
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
Relationship between CRP levels and the severity of COPD acute exacerbations among group D COPD patients.
Source: Virtual Congress 2020 – COPD phenotypes
Year: 2020
LATE-BREAKING ABSTRACT: Validation of the DECAF score to predict hospital mortality in exacerbations of COPD
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015
Serum uric acid levels and uric acid/creatinine ratio in stable COPD patients: Are these parameters efficiently predict risky patients for exacerbation and/or severity of the disease?
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
A Comparison of three severity assessment scores: APACHI II SOFA and CURB 65 for predicting inpatient mortality in patients with acute exacerbation of COPD (AECOPD)
Source: International Congress 2015 – Acute critical care: COPD, muscles and weaning
Year: 2015
Co-morbidity and hospitalization rate in patients (pts) with acute exacerbation (AE) of COPD
Source: International Congress 2015 – Different data in COPD
Year: 2015
BNP is a predictor of mortality following COPD exacerbations
Source: Annual Congress 2011 - Diagnosis and predictors of COPD exacerbation
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept